iOS
Android
Facebook
WhatsApp
Twitter
Apidra is an antidiabetic agent, used to reduce high blood sugar in patients with diabetes mellitus; it may be given to adults, adolescents and children, 6 years of age and older. Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar. It is made by biotechnology. It has a rapid onset within 10-20 minutes and a short duration, about 4 hours. Therapeutic indications: Treatment of adults, adolescents and children 6 years or older, with diabetes mellitus, where treatment with insulin is required. The potency of this preparation is stated in units. These units are exclusive to Apidra and are not the same as IU or the units used to express the potency of other insulin analogues. Apidra should be used in regimens that include an intermediate or long acting insulin or basal insulin analogue and can be used with oral hypoglycaemic agents. The dose of Apidra should be individually adjusted.
Subcutaneous use: Apidra should be given by subcutaneous injection shortly (0-15 min) before or soon after meals or by continuous subcutaneous pump infusion. Apidra should be administered subcutaneously in the abdominal wall, thigh or deltoid or by continuous infusion in the abdominal wall. Injection sites and infusion sites within an injection area (abdomen, thigh or deltoid) should be rotated from one injection to the next. The rate of absorption, and consequently the onset and duration of action, may be affected by the injection site, exercise and other variables. Subcutaneous injection in the abdominal wall ensures a slightly faster absorption than other injection sites
Contraindications: Hypersensitivity to the active substance or to any of the excipients listed in section. Hypoglycaemia. The following information is an educational aid only. It is not indicated as medical advice or alternative treatment. Consult your Doctor on safety and effectiveness.
KES 11,110.00
Delivery within 4 hours on all orders placed between 8:00 AM & 8:00 PM
